**Name of Journal: *World Journal of Hepatology***

**Manuscript NO: 39300**

**Manuscript Type: REVIEW**

**Challenge of hepatitis C in Egypt and hepatitis B in Mauritania**

Raad I *et al.* Challenge of viral hepatitis

Issam Raad, Anne-Marie Chaftari, Harrys Torres, Ehab Fahmy, Liliane Iskander Narouz, Jalen Bartek, Ray Hachem

**Issam Raad, Anne-Marie Chaftari, Harrys Torres, Ray Hachem,** Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, United States

**Ehab Fahmy,** Department of Internal Medicine, Harpur Memorial Hospital, Menouf 32951, Egypt

**Liliane Iskander Narouz,** Faculty of Nursing, Cairo University, Cairo 12613, Egypt

**Jalen Bartek,** Division of Internal Medicine, the University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, United States

**ORCID number:** Issam Raad (0000-0003-1918-1369); Anne-Marie Chaftari (0000-0001-8097-8452); Harrys Torres (0000-0003-0814-604X); Ray Hachem (0000-0002-8940-0793).

**Author contributions:** Raad I, Chaftari AM, Torres H, Fahmy E, Narouz LI, BartekJ and Hachem R contributed to conception, design, literature review, analysis, drafting and critical revision, editing, final approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Anne-Marie Chaftari, MD, Associate Professor,** Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, United States. achaftari@mdanderson.org

**Telephone:** +1-713-7923491

**Fax:** +1-713-7928233

**Received:** April 10, 2018

**Peer-review started:** April 11, 2018

**First decision:** May 2, 2018

**Revised:** May 14, 2018

**Accepted:** May 30, 2018

**Article in press:**

**Published online:**

**Abstract**

Egypt has one of the highest prevalence rates of hepatitis C virus (HCV) in the world mostly with genotype 4 that is highly associated with severe fibrosis. As a consequence, hepatocellular carcinoma has become the leading cause of cancer in this country. Mauritania is a highly endemic area for hepatitis B virus (HBV). HBV and HCV could both be iatrogenically transmitted through infected blood products, infected needles and medical equipment improperly sterilized. Adequate and efficient healthcare and public health measures with good surveillance programs, access for screening, prevention strategies, and successful treatment are needed to halt the spread of these diseases. Herein, we have reviewed the epidemiology, modes of transmission, predisposing factors, and novel treatment modalities of these viruses. We have proposed practices and interventions to decrease the risk of transmission of HCV and HBV in the affected countries including strict adherence to standard precautions in the healthcare setting, rigorous education and training of patients and healthcare providers, universal screening of blood donors, use of safety-engineered devices, proper sterilization of medical equipment, hepatitis B vaccination, as well as effective direct-acting antiviral agents for the treatment of HCV.

**Key words:** Hepatitis C virus; Hepatitis B virus; Hepatocellular carcinoma; Hospital acquired infection; World Health Organization; Hepatitis delta virus

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hepatitis C virus (HCV) and hepatitis B virus (HBV) are major public health concerns in Egypt and Mauritania. HCV and HBV can both be transmitted through medical and surgical procedures (healthcare-associated transmission) among others. Screening, prevention and treatment strategies should be emphasized in Egypt and Mauritania to prevent the spread of the disease. Direct-acting antivirals for the treatment of HCV are highly effective and well tolerated and should be made accessible and affordable to patients.

Raad I, Chaftari AM, Torres H, Fahmy E, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. *World J Hepatol* 2018; In press

**HEPATITIS C VIRUS IN EGYPT**

Over the last several years, Egypt continues to have one of the largest epidemic of hepatitis C virus (HCV) with an estimated prevalence of 10%, whereas a prevalence above 4% is considered high by World Health Organization (WHO) standards[1]. A study published in the Proceeding of the National Academy of Science (PNAS) reports more than 500000 new HCV cases yearly[2]. However, others recently estimated a lower number of new cases every year which still, remains high compared to other areas in the world[3]. Hence, viral hepatitis caused by HCV genotype 4 continues to represent the most serious public health threat currently facing Egypt[1,2].

To estimate the prevalence of HCV in Egypt a national survey was conducted in 2015 known as the Egyptian Health Issues Survey (EHIS). This survey was a cross-sectional household survey of 16003 who were identified between the ages of 15 and 59 and had blood testing for HCV[1]. The results of this survey were compared to another cross-sectional national survey conducted in 2008 known as the Egyptian Demographic Health Survey (EDHS) in which 12008 Egyptian were interviewed[4]. The 2015 survey (EHIS) reported a prevalence of 10% for HCV antibody and 7% for HCV RNA. This reflected an estimated 29% reduction in HCV RNA prevalence compared to the 2008 national survey (EDHS) that could be related to the disappearance of the highly infected group that was treated with reused syringes during the shistosomiasis treatment campaign in the 1960s and 1970s[1]. Hence, by 2015 this highly infected older age group disappeared due to differential age related migration and mortality (particularly since the survey excluded individuals that are 60 years or older). Furthermore, when a shift adjustment was made (by seven years) the age specific prevalence of HCV RNA positivity was matched and was comparable in the 2008 surveillance (EDHS) compared to the 2015 surveillance (EHIS). Hence, these surveys represent an underestimate of the true prevalence of the HCV infections in Egypt, particularly since the rate of infection is among elderly patients above 60 years who acquired the infections in the 1960s and 1970s whereas these surveys were limited only to individuals with an age range of 15-59 years[1].

Based on the above and given the population of Egypt which exceeds 95 million, we estimate that more than 6.5 million Egyptians are infected with the HCV virus and most of those are caused by a genotype 4. Several genotypic studies have shown that genotype 4 of HCV accounts for 93.1% of HCV infections and most (80.6%) of the Egyptians infected with HCV4 belong to subtype 4A[5-7]. It is likely that the subtype 4A was the main strain associated with antischistosomal therapy epidemic that occurred in the 1960s and 1970s and which was associated with the reuse of needles[8,9]. In fact HCV4 is the predominant HCV genotype in the Middle East and North Africa which accounts for 59% of HCV infections in Syria, 53% in Iraq, 54% in Kuwait, 64% in Palestine and it is also reported to be a dominant genotype in Qatar, Saudi Arabia, and Libya[5,6,10,11]. It is also common in other parts of the Middle East such as Lebanon, Oman, UAE and possibly related to the migration of Egyptians to these areas who represent a major workforce in some of these Middle Eastern countries[5,11].

Furthermore, there is evidence that HCV4 is a highly pathogenic virus. Wali *et al*[12] have demonstrated that HCV4 was significantly more associated with fibrosis progression, severe fibrosis development and confluent necrosis than other non-genotype 4 HCV infected patients. In addition, hepatocellular carcinoma (HCC) in Egypt is a leading cause of cancer and cancer mortality among men whereby more than 84% of Egyptian patients with HCC are positive with HCV4[13,14]. Chronic infection that could lead to severe fibrosis and cirrhosis can occur in 50%-85% of HCV patients[15,16]. Given the decline in the economic and healthcare conditions, nationwide efforts to control the spread of HCV infection have been disrupted for several years.

The iatrogenic spread of HCV genotype 4 in Egypt due to the improper dental instruments sterilization has been a major concern[17]. Furthermore, between 46%-100% of hemodialysis patients and 11%-81.6% of patients who received multi-transfusions were found to be seropositive for HCV[18].

Despite all the effort done by the ministry of health and population (MOHP) in Egypt to control infection, healthcare-associated infection (HAI) remains one of the most common cause of HCV infection in Egypt, related to the overuse of contaminated needles and syringes[2]. In addition, healthcare workers in Egypt and many Middle Eastern countries have the highest rates of needle stick injuries worldwide[19,20]. Hence, unsafe medical and dental practices including reuse of medical devices, inadequate sterilization of surgical and interventional equipment, poor aseptic techniques practiced during invasive procedures, circumcisions or deliveries of neonates by providers, unsafe injections and limited testing of blood product transfusions for HCV have all contributed to high iatrogenic transmission of HCV in Egypt[21-23]. These factors play an important role in the transmission of HCV in Egypt. Table 1 outlines the risk factors for the transmission of HCV in Egypt through the healthcare system, and the proposed infection prevention interventions that could control this transmission.

To control this self-perpetuating HCV epidemic in Egypt, a health initiative was started in 2017 to screen all governorates of Egypt called “Egypt without Virus C, 2020” in cooperation with Tahya Misr Fund[24]. A concerted effort should be made towards universal screening of all patients going through the healthcare system, early detection of HCV, early treatment using direct acting antiviral (DAA) regimen with simultaneous implementation of strict infection control and prevention policies within the healthcare system.

Egypt also developed a strategy for prevention and control of viral hepatitis (2008-2014) in collaboration with WHO, CDC and Pasteur[25]. The National Committee for Control of Viral Hepatitis (NCCVH) in affiliation to the MOHP established a large model of care in Egypt since 2006 that aims at elimination of HCV in Egypt and delivering DAAs for all patients at the expense of the Government[25,26]. However, the limited resources, the unmet needs and suboptimal access to care, and the low rates of patients’ follow-up hinder the success of the program[27,28].

Most of the individuals living with viral hepatitis caused by HCV are asymptomatic and, hence, remain unaware of their illness for decades even though liver damage is occurring. Given the high prevalence of HCV in Egypt, universal surveillance through rapid enzyme immunoassay testing of all patients going through the healthcare system would detect a large number of asymptomatic patients. With the advent of DAA and the demonstration of high cure rates (sustained virologic response or SVR) of over 90%, including genotype 4 infected patients. The DAAs are also associated with minimal side effects and relatively short duration of treatment when compared to interferon based treatments.

Hence, it is possible to virologically cure the majority of these patients, particularly if the patient is treated in the early phase when they are not suffering from decompensated liver disease or cirrhosis[29-32]. Curing these patients would preempt the morbidity and mortality associated with subsequent liver cirrhosis and HCC. SVR after non-interferon DAA regimens is associated with improvement in liver fibrosis and necrosis in up to 73 % of patients with reversal of cirrhosis in 49% of the cases[33]. Emerging data with DAAs show significant improvement of liver stiffness that has been reported in patients with HCV-associated advanced liver disease[34]. Recent study has shown that DAA-induced SVR was associated with 71% reduction in HCC[35].

Early treatment of HCV infection, regardless of the infecting genotype, may also reduce the risk of extrahepatic complications, including mixed cryoglobulinemia, porphyria cutanea tarda, diabetes mellitus, cardiovascular disease, renal diseases, and B-cell non-Hodgkin lymphoma[36-38].

Given the availability of generic versions of DAAs (particularly sofosbuvir at an affordable low cost), early treatment can be widely used and, hence, could effectively contribute to the elimination of HCV viral Hepatitis in Egypt[3]. The World Health Organization (WHO) reported that after generic sofosbuvir became available in Egypt at a cost of $153 for a 12-wk course, approximately half a million patients with chronic HCV were treated with this drug since January 2016[3,39]. Our team conducted a large surveillance study on patients evaluated at Harpur Memorial Hospital in the Delta area of Menouf, Egypt, involving 729 adult patients (18-65 years) who were evaluated for health-related illnesses not associated with hepatitis or liver diseases between January 2012-January 2013. All patients who consented were screened by a rapid enzyme immunoassay (ELISA) to detect the presence of HCV antibodies and determine the prevalence of HCV (HCV antibodies. The reactive Elisa rapid test samples were further confirmed for HCV antibody positivity by the chemiluminescent microplate immunoassay (CIA). Subsequently, CIA HCV antibiody positive samples were tested further for HCV RNA by quantitative real time PCR. We identified 146 patients (20%) who were found to be positive for HCV which was later confirmed by the ELISA antibody test and HCV-RNA levels (viral load). Of interest is that 119 (82% of the 146 patients) with a positive test had no risk factors for developing HCV such as a surgical procedure, dental extraction, needle stick injuries, blood transfusions and other risk factors listed in Table 1 in the prior five years. All of the 146 patients with positive HCV in the study were asymptomatic with no symptoms of liver disease. Therefore, this study highlights the importance of universal surveillance in the general population suggested by WHO in countries with high HCV antibody seroprevalence (≥ 2%) that will lead to the early detection of HCV in asymptomatic patients and ultimately lead to high cure rates after using DAA[29-32,40]​.

In addition to the universal surveillance, early diagnosis and early treatment of HCV in Egypt, promotion of infection prevention and control procedures in a healthcare setting is of paramount importance in controlling HCV transmission[40]. These infection control policies and practices should prohibit reuse of medical devices or needles, emphasize appropriate sterilization of surgical and dental instruments, promote the use of safe injectables, protect against needle stick and other healthcare related injuries as well as testing all blood donors and adhere to appropriate healthcare waste management. This involves a large scale training of healthcare professionals in Egypt on infection control practices and includes new safeguard technologies such as the auto-disable syringes (Table 1).

The conventional combination regimen of pegylated-interferon and ribavirin alone has demonstrated low SVR rates against genotype 4 of approximately 30% after 48 wk of treatment with poor tolerance of the regimen[41,42]. However, several DAAs have been approved in the United States and Europe that showed highly promising results and, hence, they have changed the treatment paradigm for chronic HCV infections in general inclusing genotype 4 (Table 2)[43,44]. The DAA regimen should be individualized mostly on the basis of the patient’s prior antiviral therapy, presence of cirrhosis, availability, cost and drug-drug interactions with concomitant medications[43]. In most of these regimens, the treatment duration extended between 12-24 wk[29-32,43-45].

One of the first interferon-free regimen used in treatment of genotype 4 HCV consisting of sofosbuvir plus ribavirin showed that 12 wk of treatment was associated with overall lower SVR rates compared to 24 wk and hence this regimen was approved for 24 wk[29].

In particular, several fixed dose combination regimens such as ledipasvir-sofosbuvir[30,46,47], sofosbuvir-velpatasvir[31,48], and glecaprevir/pibrentasvir[49,50], have demonstrated efficacy with SVR that exceeds 90% after 8-12 wk of treatment of HCV 4 and are unique in that they achieve successful outcome with once daily dosing and without the need to administer ribavirin in the treatment of genotype 4 HCV. Only glecaprevir/pibrentasvir can be used for 8 wk in the subset of treatment-naive or peginterferon/ribavirin-experienced genotype 4 patients without cirrhosis[43,49,50].

Ledipasvir-sofosbuvir is available and widely used in the treatment of genotype 4 HCV patients in Egypt, in open label phase 2 trial Kohli *et al*[30] showed that ledipasvir-sofosbuvir treatment of patients with HCV genotype 4 for 12 wk resulted in 100% SVR 12 and was well tolerated with minimal mild adverse events. Crespo *et al*[47] reported on the effectiveness and the safety of this once daily oral combination in the treatment of hepatitis C genotype 4 infections showing an overall 95.4% SVR 12 response with a respective 100% SVR 12 response in patients without cirrhosis. In patients with cirrhosis 12-wk treatment with ledipasvir-sofosbuvir without ribavirin had an equivalent successful outcome to this once daily combination with ribavirin for 12 wk or 24 wk[47]. However, many of the genotype 4 HCV patients in Egypt are elderly patients with some renal insufficiency or reflux disorder requiring proton pump inhibitors (PPIs) which might limit the activity and the use of the drug in this population[51,52].

Sofosbuvir-Velpatasvir has also demonstrated high efficacy in the treatment of patients with genotype 4 HCV infections irrespective of treatment history (treatment naïve or experienced) or the presence of cirrhosis[31,48]. In a study by Feld *et al*[31] 100% of the 116 patients with genotype 4 infection achieved SVR 12 following a 12-wk treatment of sofosbuvir-Velpatasvir. Similarly this regimen was highly effective in genotype 4 HCV infections and was well tolerated with only serious adverse events occurring in only 2% of those who received this regimen[48].

The fixed dose combination of glecaprevir-pibrentasvir given once daily in three pills was uniquely effective in the treatment of HCV genotype 4 infected patients when given for only eight weeks in patients without cirrhosis resulting in an SVR 12 response rate of 93% in this patient population[49,50]. Furthermore, in 16 patients with cirrhosis who received 12 wk of this fixed combination 100% SVR 12 was achieved. It is to note that the HCV genotype 4 patients without cirrhosis who did not achieve SVR 12 with the eight week regimen were either patients who had incomplete data or discontinued therapy prematurely[50]. The advantage of this fixed dose combination regimen of glecaprevir-pibrentasvir is that it can be given in patients in any degree of renal impairment unlike to ledipasvir/sofosbuvir, sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir[49,50].

**HEPATITIS B IN MAURITANIA**

Hepatitis B virus (HBV) is a major cause for liver disease worldwide particularly in Mauritania[53]. There are approximately two billion people who have been infected with HBV, of which 400 million people are infected chronically and of whom 65 million reside in Africa. HBV infection leads to 0.5-1.2 million deaths annually due to liver cirrhosis and HCC. Sub-Saharan Africa has a high HBV prevalence rate of 16.16%[54,55]. Mauritania remains a hyper-endemic area for HBV. Studies in Mauritania on the epidemiology of HBV by Mansour *et al*[56], have shown a high prevalence of HBsAg positivity in blood donors, mostly between the age of 21-30, despite HBV vaccination of children and newborns since 2000[57]. Moreover, high HBV DNA levels was shown to be significantly and independently associated with incidence of cirrhosis and HCC.

Co-infection with hepatitis delta virus (HDV)[58], is also endemic in Mauritania[59]. There is high prevalence of HBV (20%) and HDV (30%). HDV infection tends to occur early, affecting mainly children and young adults leading to chronic hepatitis. The natural course of chronic HDV is rapid progression to cirrhosis and liver related complications including hepatocellular carcinoma[60,61].

The modes of transmission in Mauritania for HBV and HDV are social close contact, sexual contact, sharing needles and other forms of blood exchange, as well as maternal-fetal transmission during delivery (Table 3). Interfamilial transmission is common and may be facilitated by poor hygiene. Thus, socially and economically disadvantaged populations like Mauritania are more affected. Children infected perinatally with HBV are asymptomatic and 25% die in adulthood from cirrhosis complications or HCC[62].

HCC remains a major cause of mortality due to the limited therapeutic options. The aim should focus on prevention. Effective vaccine for HBV is available and was recommended by WHO to be included in the national immunization program. However, not all countries have adopted and implemented this recommendation effectively, including Mauritania which rank among the countries with the highest mortality of HBV associated HCC[62].

Hepatitis B vaccination is the best strategy to prevent this infection, and decrease its incidence in the young population[63]. Vaccination is highly recommended in high prevalence areas like Mauritania and the vaccines should be given to all infants at the time of birth, children and adolescents as well as adults with risk factors that are included in Table 3. In addition booster doses of hepatitis B vaccine are recommended in hemodialysis and in immunocompromised person. The high cost of the vaccine and the lack of the infrastructure to deliver the vaccines do impact the implementation of the universal vaccination program in Mauritania. Prevalence rates of hepatitis B and children vaccination rates in various African region have been published[64]. However, given the limited data available from the unaccounted home births, the reported vaccination rates could be inflated and the prevalence of the disease understated. Therefore public health action is urgently needed. A multifaceted approach to improve the socioeconomic conditions, increase the awareness of the risk of transmission, aggressive vaccination campaigns, and public health intervention are strongly needed to prevent viral transmission. Also a regional specific clinical guideline for screening, targeting infection control measure and the use of ultra-sonographic tools in the highest risk setting such as healthcare, dentistry and personal grooming service center are needed. In addition, enhanced access to health care services, and providing public funds for treating HBV and HDV may help to optimize management of infected patients.

Patients with acute hepatitis B do not require the antiviral medication. Most patients will recover spontaneously. Supportive care with hydration and follow up regularly with their physician is recommended. However, patients with chronic hepatitis B are more likely to require antiviral medications. Its purpose is to stop any further damage to the liver by slowing the multiplication of the virus. Therapy should be given to the following patients: patients with chronic hepatitis B with HBV DNA > 20000 IU/mL and with liver alanine aminotransferase > 2 × upper limit of normal, patients with evidence of fibrosis or moderate to severe hepatitis on Liver biopsy irrespective of hepatitis B DNA level, and patients with Cirrhosis associated with chronic HBV irrespective of hepatitis B DNA level.

Nucleoside analogue is the preferred agents and they are very effective at viral suppression and also they have a high barrier to drug resistance. The current first line therapy are Entecavir 0.5 mg/d × 48 wk orally, Tenofovir 300 mg/d × 48 wk orally[65], Pegylated interferon in noncirrhotic HbeAg-positive patients is also an option[66]. However, most patients require lifelong therapy because relapse is common after discontinuation of therapy may be necessary to prevent relapsed[67,68]. Unfortunately, most of the Mauritanian with chronic HBV infection who are eligible for this therapy cannot afford it. Less of 1% of individuals eligible for antiviral therapy receive HBV treatment. In mothers with high viral load, the antiviral treatment rate to reduce mother-to-child transmission is even lower[69].

**REFERENCES**

1 **Kandeel A**, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. *Liver Int* 2017; **37**: 45-53 [PMID: 27275625 DOI: 10.1111/liv.13186]

2 **Miller FD**, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. *Proc Natl Acad Sci USA* 2010; **107**: 14757-14762 [PMID: 20696911 DOI: 10.1073/pnas.1008877107]

3 **Hill AM**, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. *J Virus Erad* 2017; **3**: 117-123 [PMID: 28758018]

4 **El-Zanaty F**, Way A. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International, 2009

5 **Zayed RA**, Omran D, Zayed AA, Elmessery LO. Determinants of Infection Outcome in HCV-Genotype 4. *Viral Immunol* 2017; **30**: 560-567 [PMID: 28731371 DOI: 10.1089/vim.2017.0071]

6 **Petruzziello A**, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. *World J Gastroenterol* 2016; **22**: 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824]

7 **Ray SC**, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. *J Infect Dis* 2000; **182**: 698-707 [PMID: 10950762 DOI: 10.1086/315786]

8 **Frank C**, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000; **355**: 887-891 [PMID: 10752705 DOI: 10.1016/S0140-6736(99)06527-7]

9 **Lavanchy D**, McMahon B. Worldwide Prevalence and Prevention of Hepatitis C. In: Liang TJ, Hoofnagle JH, editors. Hepatitis C. San Diego: Acedemic Press, 2000: 185-201 [DOI: 10.1016/S1874-5326(00)80014-9]

10 **Sharara AI**, Ramia S, Ramlawi F, Fares JE, Klayme S, Naman R. Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: comparison of data with that from other Middle Eastern countries. *Epidemiol Infect* 2007; **135**: 427-432 [PMID: 16848924 DOI: 10.1017/S0950268806006911]

11 **Mahmud S**, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. *J Med Virol* 2018; **90**: 131-141 [PMID: 28842995 DOI: 10.1002/jmv.24921]

12 **Wali MH**, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. *Liver Transpl* 2003; **9**: 796-804 [PMID: 12884191 DOI: 10.1053/jlts.2003.50164]

13 **Lehman EM**, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. *Int J Cancer* 2009; **124**: 690-697 [PMID: 18973270 DOI: 10.1002/ijc.23937]

14 **Ibrahim AS**, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. *J Cancer Epidemiol* 2014; **2014**: 437971 [PMID: 25328522 DOI: 10.1155/2014/437971]

15 **McCombs J**, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L'italien G, Juday T, Yuan Y. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. *JAMA Intern Med* 2014; **174**: 204-212 [PMID: 24193887 DOI: 10.1001/jamainternmed.2013.12505]

16 **van der Meer AJ**, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, Janssen HL. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. *JAMA* 2014; **312**: 1927-1928 [PMID: 25387192 DOI: 10.1001/jama.2014.12627]

17 **Hashish MH**, Selim HS, Elshazly SA, Diab HH, Elsayed NM. Screening for the hepatitis C virus in some dental clinics in Alexandria, Egypt. *J Egypt Public Health Assoc* 2012; **87**: 109-115 [PMID: 23196884 DOI: 10.1097/01.EPX.0000421670.02166.ec]

18 **Mohamoud YA**, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. *BMC Infect Dis* 2013; **13**: 288 [PMID: 23799878 DOI: 10.1186/1471-2334-13-288]

19 **Zafar A**, Aslam N, Nasir N, Meraj R, Mehraj V. Knowledge, attitudes and practices of health care workers regarding needle stick injuries at a tertiary care hospital in Pakistan. *J Pak Med Assoc* 2008; **58**: 57-60 [PMID: 18333520]

20 **Kennedy M**, O'Reilly D, Mah MW. The use of a quality-improvement approach to reduce needlestick injuries in a Saudi Arabian hospital. *Clin Perform Qual Health Care* 1998; **6**: 79-83 [PMID: 10180126]

21 **El Katsha S**, Labeeb S, Watts S, Younis A. Informal health providers and the transmission of hepatitis C virus: pilot study in two Egyptian villages. *East Mediterr Health J* 2006; **12**: 758-767 [PMID: 17333820]

22 **Stoszek SK**, Abdel-Hamid M, Narooz S, El Daly M, Saleh DA, Mikhail N, Kassem E, Hawash Y, El Kafrawy S, Said A, El Batanony M, Shebl FM, Sayed M, Sharaf S, Fix AD, Strickland GT. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. *Trans R Soc Trop Med Hyg* 2006; **100**: 102-107 [PMID: 16289168 DOI: 10.1016/j.trstmh.2004.12.005]

23 **Talaat M**, Kandeel A, El-Shoubary W, Bodenschatz C, Khairy I, Oun S, Mahoney FJ. Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt. *Am J Infect Control* 2003; **31**: 469-474 [PMID: 14647109 DOI: 10.1016/j.ajic.2003.03.003]

24 **Reuters**. Egypt to be free of hepatitis-C by 2020: health minister. Available from: URL: http://www.egyptindependent.com/egypt-be-free-hepatitis-c-2020-health-minister/

25 **El-Akel W**, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K, Kabil K, Hassany M, Shawky A, Yosry A, Shaker MK, ElShazly Y, Waked I, Esmat G, Doss W. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. *J Viral Hepat* 2017; **24**: 262-267 [PMID: 28145032 DOI: 10.1111/jvh.12668]

26 **Elsharkawy A**, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M, Abdelaziz AO, Shaker MK, Yosry A, Doss W, El-Shazly Y, Esmat G, Waked I. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. *J Hepatol* 2017; **pii**: S0168-8278(17)32478-9 [PMID: 29223371 DOI: 10.1016/j.jhep.2017.11.034]

27 **Lemoine M**, Mohamed Z, Chevaliez S, Shimakawa Y, Rwegasha J. Role of hepatitis C virus core antigen assay in hepatitis C care in Africa. *Lancet Gastroenterol Hepatol* 2018; **3**: 223-224 [PMID: 29533193 DOI: 10.1016/S2468-1253(18)30039-6]

28 **Elgharably A**, Gomaa AI, Crossey MM, Norsworthy PJ, Waked I, Taylor-Robinson SD. Hepatitis C in Egypt - past, present, and future. *Int J Gen Med* 2016; **10**: 1-6 [PMID: 28053553 DOI: 10.2147/IJGM.S119301]

29 **Ruane PJ**, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, Riad J, Mikhail S, Kersey K, Jiang D, Massetto B, Doehle B, Kirby BJ, Knox SJ, McHutchison JG, Symonds WT. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. *J Hepatol* 2015; **62**: 1040-1046 [PMID: 25450208 DOI: 10.1016/j.jhep.2014.10.044]

30 **Kohli A**, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. *Lancet Infect Dis* 2015; **15**: 1049-1054 [PMID: 26187031 DOI: 10.1016/S1473-3099(15)00157-7]

31 **Feld JJ**, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. *N Engl J Med* 2015; **373**: 2599-2607 [PMID: 26571066 DOI: 10.1056/NEJMoa1512610]

32 **Asselah T**, Reesink H, Gerstoft J, de Ledinghen V, Pockros P, Robertson M, Hwang P, Wahl J, Nguyen BY, Barr E, Talwani R, Serfaty L. High Efficacy of Elbasvir and grazoprevir With or Without Ribavirin in 103 Treatment-Naive and Experienced Patients With HCV Genotype 4 Infection: A Pooled Analysis 66th Annual Meeting of the American Association for the Study of Liver Diseases; Nov 13-17; Boston, MA, 2015

33 **Poynard T**, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology* 2002; **122**: 1303-1313 [PMID: 11984517 DOI: 10.1053/gast.2002.33023]

34 **Knop V**, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. *J Viral Hepat* 2016; **23**: 994-1002 [PMID: 27500382 DOI: 10.1111/jvh.12578]

35 **Ioannou GN**, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. *J Hepatol* 2017; **pii**: S0168-8278(17)32273-0 [PMID: 28887168 DOI: 10.1016/j.jhep.2017.08.030]

36 **Hsu YC**, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. *Gut* 2015; **64**: 495-503 [PMID: 25398770 DOI: 10.1136/gutjnl-2014-308163]

37 **Torres HA**, Mahale P. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization. *Liver Int* 2015; **35**: 1661-1664 [PMID: 25779000 DOI: 10.1111/liv.12825]

38 **Mahale P**, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, Kramer JR. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. *Gut* 2018; **67**: 553-561 [PMID: 28634198 DOI: 10.1136/gutjnl-2017-313983]

39 **World Health Organization**. Global Report on Access to Hepatitis C Treatment. Focus on overcoming barriers. Available from: URL: http://apps.who.int/iris/bitstream/10665/250625/1/WHO-HIV-2016.20-eng.pdf?ua=1/

40 **World Health Organization**. Guidelines on Hepatitis B and C Testing. Available from: URL: http://apps.who.int/iris/bitstream/handle/10665/254621/9789241549981-eng.pdf?sequence=1

41 **Legrand-Abravanel F**, Nicot F, Boulestin A, Sandres-Sauné K, Vinel JP, Alric L, Izopet J. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. *J Med Virol* 2005; **77**: 66-69 [PMID: 16032749 DOI: 10.1002/jmv.20414]

42 **Derbala M**, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. *J Viral Hepat* 2005; **12**: 380-385 [PMID: 15985008 DOI: 10.1111/j.1365-2893.2005.00604.x]

43 **American Association for the Study of Liver Diseases**, Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available from: URL: https://www.hcvguidelines.org/

44 **European Association for Study of Liver**. EASL Recommendations on Treatment of Hepatitis C 2015. *J Hepatol* 2015; **63**: 199-236 [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025]

45 **Asselah T**, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Talwani R, Serfaty L. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. *Liver Int* 2018; Epub ahead of print [PMID: 29461687 DOI: 10.1111/liv.13727]

46 **Nehra V**, Tan EM, Rizza SA, Temesgen Z. Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection. *Drugs Today* (Barc) 2016; **52**: 111-117 [PMID: 27092340 DOI: 10.1358/dot.2016.52.2.2449840]

47 **Crespo J**, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. *Clin Gastroenterol Hepatol* 2017; **15**: 945-949.e1 [PMID: 28238958 DOI: 10.1016/j.cgh.2017.02.020]

48 **Asselah T**, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Gane EJ, Feld JJ, Mangia A. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. *Liver Int* 2018; **38**: 443-450 [PMID: 28756625 DOI: 10.1111/liv.13534]

49 **Asselah T**, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. *Clin Gastroenterol Hepatol* 2018; **16**: 417-426 [PMID: 28951228 DOI: 10.1016/j.cgh.2017.09.027]

50 **Forns X**, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. *Lancet Infect Dis* 2017; **17**: 1062-1068 [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6]

51 **Hill L**. Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment. *Top Antivir Med* 2015; **23**: 92-96 [PMID: 26200709]

52 **Cornpropst M**, Denning J, Clemons D, Marbury T, Alcorn H, Smith W, Sale M, Fang L, Berrey M, Symonds W. The Effect of Renal Impairment and End Stage Renal Disease on the Single-Dose Pharmacokinetics of GS-7977. European Association for the Study of the Liver (EASL) 47th Annual Meeting; April 18th-22nd Barcelona, Spain, 2012

53 Hepatitis B vaccines. *Wkly Epidemiol Rec* 2004; **79**: 255-263 [PMID: 15344666]

54 **Kramvis A**, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. *Hepatol Res* 2007; **37**: S9-S19 [PMID: 17627641 DOI: 10.1111/j.1872-034X.2007.00098.x]

55 **Schweitzer A**, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015; **386**: 1546-1555 [PMID: 26231459 DOI: 10.1016/S0140-6736(15)61412-X]

56 **Boushab BM**, Mohamed Limame OCM, Fatim Zahra FM, Mamoudou S, Roseline Darnycka BM, Saliou SM. Estimation of seroprevalence of HIV, hepatitis B and C virus and syphilis among blood donors in the hospital of Aïoun, Mauritania. *Pan Afr Med J* 2017; **28**: 118 [PMID: 29515736 DOI: 10.11604/pamj.2017.28.118.12465]

57 **Mansour W**, Fall-Malick Z, Sidiya A, Elkhalil I, Abdou Chekaraou M, Lô B. High Prevalence of Hepatitis Delta Virus in Adults and Pregnant Women in Mauritania. Monothematic conference "Hepatitis delta" European Association for the Study of the liver; 2010 Sep 24-26; Istanbul, Turkey; Poster A61

58 **Taylor JM**. Structure and replication of hepatitis delta virus RNA. *Curr Top Microbiol Immunol* 2006; **307**: 1-23 [PMID: 16903218 DOI: 10.1007/3-540-29802-9\_1]

59 **Hughes SA**, Wedemeyer H, Harrison PM. Hepatitis delta virus. *Lancet* 2011; **378**: 73-85 [PMID: 21511329 DOI: 10.1016/S0140-6736(10)61931-9]

60 **Wedemeyer H**, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 31-40 [PMID: 20051970 DOI: 10.1038/nrgastro.2009.205]

61 **Lunel-Fabiani F**, Mansour W, Amar AO, Aye M, Le Gal F, Malick FZ, Baïdy L, Brichler S, Veillon P, Ducancelle A, Gordien E, Rosenheim M. Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: a cross sectional study. *J Infect* 2013; **67**: 448-457 [PMID: 23796871 DOI: 10.1016/j.jinf.2013.06.008]

62 **Khan G**, Hashim MJ. Burden of virus-associated liver cancer in the Arab world, 1990-2010. *Asian Pac J Cancer Prev* 2015; **16**: 265-270 [PMID: 25640363 DOI: 10.7314/APJCP.2015.16.1.265]

63 **Ko SC**, Schillie SF, Walker T, Veselsky SL, Nelson NP, Lazaroff J, Crowley S, Dusek C, Loggins K, Onye K, Fenlon N, Murphy TV. Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women. *Vaccine* 2014; **32**: 2127-2133 [PMID: 24560676 DOI: 10.1016/j.vaccine.2014.01.099]

64 **Breakwell L**, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. The status of hepatitis B control in the African region. *Pan Afr Med J* 2017; **27**: 17 [PMID: 29296152 DOI: 10.11604/pamj.supp.2017.27.3.11981]

65 **Han SH**, Tran TT. Management of Chronic Hepatitis B: An Overview of Practice Guidelines for Primary Care Providers. *J Am Board Fam Med* 2015; **28**: 822-837 [PMID: 26546661 DOI: 10.3122/jabfm.2015.06.140331]

66 **Terrault NA**, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology* 2016; **63**: 261-283 [PMID: 26566064 DOI: 10.1002/hep.28156]

67 **Chen CH**, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, Lee CM. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. *Clin Gastroenterol Hepatol* 2015; **13**: 1984-92.e1 [PMID: 26073492 DOI: 10.1016/j.cgh.2015.06.002]

68 **Seto WK**, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. *Gut* 2015; **64**: 667-672 [PMID: 24833635 DOI: 10.1136/gutjnl-2014-307237]

69 **Polaris Observatory Collaborators**. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol* 2018; **3**: 383-403 [PMID: 29599078 DOI: 10.1016/S2468-1253(18)30056-6]

**P-Reviewer:** Moini M, Sazci A, Zheng SJ **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**Table 1 Risk factors of the transmission of hepatitis C in Egypt through the healthcare system and proposed interventions**

|  |  |
| --- | --- |
| **Risk factors** | **Proposed interventions** |
| Needle stick injuries or other injuries | Institute infection control and occupational health programs in all healthcare facilities to reduce occupational exposure, protect against needle stick and other healthcare related injuriesAdequate education and training of healthcare providersUse of safety-engineered devices such as needleless intravenous medication systems, blunted suture needlesUse of needle disposal containers |
| Surgical or invasive interventions, dental procedures | Appropriate sterilization of surgical and dental instrumentsGood aseptic techniques practiced during invasive proceduresProvide personal protective equipment such as gloves, gowns, face/eye shields, to be used during procedures with anticipated blood exposure |
| Exposure to medical equipment, hemodialysis machines and procedures | Strict infection control and prevention policiesUniversal precautions should be used when caring for all patients |
| Injection and IV insertion | Use of self-sheathing needles, needleless connectors, needleless intravenous medication system and needle disposal containers |
| Blood transfusion from poorly screened individuals (false negative anti-HCV) | Universal screening of all donors |
| Organ donation | Universal screening of all donors |

HCV: Hepatitis C virus.

**Table 2 Direct-acting antiviral regimens available to treat hepatitis C virus genotype 4**

|  |  |
| --- | --- |
| **1Combination regimen[43,44]** | **Duration (wk)** |
| **Sofosbuvir-Ledipasvir** | 12 |
| **Sofosbuvir-Velpatasvir** | 12 |
| **Glecaprevir-pibrentasvir** | 8 (without cirrhosis)12 (with cirrhosis) |
| **Sofosbuvir-velpatasvir-voxilaprevir** | 12 |
| **Ombitasvir-paritaprevir-ritonavir ± ribavirin** | 12 |
| **Elbasvir-grazoprevir ± ribavirin** | 12-16 |
| Elbasvir-grazoprevir  | 12 (treatment naïve) |
| Elbasvir-grazoprevir + ribavirin | 16 (treatment experienced) |
| **Sofosbuvir + ribavirin** | 24 |
| **Sofosbuvir + daclatasvir ± ribavirin** | 12 |
| **Sofosbuvir + simeprivir ± ribavirin** | 12-24 |

1The informations from the table are taken from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) hepatitis C virus guidelines.

**Table 3 Risk factors of transmission of hepatitis B in Mauritania and proposed interventions**

|  |  |
| --- | --- |
| **Risk factors** | **Proposed interventions** |
| Direct contact with infected blood and or handling blood or body fluids (job exposure) | Rigorous adherence to standard precautions in healthcare settingsCompletely avoid sharing needles or re-using disposable devicesEducation of healthcare providers and patientsHepatitis B vaccinations and assessment of response to vaccine (hepatitis B surface antibody) Use of safety-engineered devices, and needless infusion systemsUse of sharp object disposal containersStrict infection control measures upon cleaning and reusing medical equipmentsAppropriate screening of blood donorsPost-exposure prophylaxisAntiviral therapy |
| Sharing needles or other equipment (such as cotton, spoons, and water) to inject drugs |
| Hemodialysis |
| Intimate contact with a person with HBV | Hepatitis B vaccinationAvoid sharing toothbrushes, razors, *etc.* |
| Multiple sex partners or having unprotected sex with someone who is infected with the virus | Hepatitis B vaccinationProtected sexual intercourse |
| Mother-to-Child transmission | Screening pregnant womenAntiviral therapy to pregnant women with high DNA levelsPassive-active immunization of newborns of mothers with HBVUniversal vaccination of newborns |
| Body piercings, tattoos or acupuncture  | Avoid body piercing and tattoosStrict infection control and prevention policies |
| IV drug users | Avoid sharing syringes and needles |

HBV: Hepatitis B virus.